Edition:
United Kingdom

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

19.70USD
22 Nov 2017
Change (% chg)

$-0.12 (-0.61%)
Prev Close
$19.82
Open
$19.81
Day's High
$20.04
Day's Low
$19.45
Volume
305,254
Avg. Vol
403,920
52-wk High
$21.95
52-wk Low
$3.85

Select another date:

Thu, Nov 2 2017

BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11

* Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update

BRIEF-Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2

* Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2 Source text for Eikon: Further company coverage:

BRIEF-Spectrum Pharma to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

* Spectrum Pharmaceuticals announces agreements to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility

* Spectrum Pharmaceuticals Inc provides update on at-the-market facility

BRIEF-Spectrum Pharma starts phase 3 qapzola trial

* Spectrum pharmaceuticals announces initiation of the registrational phase 3 trial of qapzola™ (apaziquone) in patients with non-muscle invasive bladder cancer (nmibc)

BRIEF-Spectrum Pharma enters into an at market issuance sales agreement

* Spectrum Pharmaceuticals Inc - on August 4, 2017, co entered into an at market issuance sales agreement - sec filing

BRIEF-Spectrum Pharmaceuticals Q2 loss per share $0.26

* Spectrum Pharmaceuticals reports second quarter 2017 financial results and pipeline update

BRIEF-Spectrum Pharmaceuticals announces ‍enrollment in Rolontis phase 3 advance pivotal study​

* Spectrum Pharmaceuticals Inc - ‍enrollment with 405 patients randomized in rolontis phase 3 advance pivotal study​

BRIEF-Spectrum Pharmaceuticals says stockholders did not approve by advisory vote executive compensation at annual meeting

* Spectrum Pharmaceuticals Inc - stockholders did not approve by advisory vote executive compensation at annual meeting Source text: (http://bit.ly/2sHq6yo) Further company coverage:

Select another date: